Aleksandra Dybcio

Aleksandra Dybcio

Auto-generated profile, based on publicly available information

Aleksandra Dybcio

Medical University of Lublin

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2025 in Medical Science Monitor
Verified
Journal Article
Open access
IMIzabela Mamcarz
Izabela Mamcarz
MPMarcelina Podleśna
Marcelina Podleśna
EBEmanuela Bis
Emanuela Bis
ABAleksandra Białek
Aleksandra Białek
KCKacper Curzytek
Kacper Curzytek
ASAgnieszka Surowiecka
Agnieszka Surowiecka
AI-Based Facial Analysis vs Self-Report: A Pilot Study Using Insights From Pre-Procedural Psychological Tests - Article abstract #947227

7 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ADAleksandra Joanna Dybcio
Aleksandra Joanna Dybcio
MKMikhail Kazachok
Mikhail Kazachok
SPSzymon Paruszewski
Szymon Paruszewski
KKKatarzyna Kupczyk
Katarzyna Kupczyk
MJMikołaj Jońca
Mikołaj Jońca
JKJulia Kupczak
Julia Kupczak
Background. In the early 2020s, the global ADHD landscape shifted radically, marked by surging public interest, social media discourse, and rising diagnosis rates. The review investigates whether it reflects enhanced clinical awareness or a trend toward overdiagnosis. Comparing diagnostic trajectories, the study addresses the issue of overdiagnosis in certain populations and persistent underdiagnosis in others, followed by age and gender influence prevalence rates. Aim. The study aims to analyze epidemiological trends in ADHD diagnosis among children and adults, assesses overdiagnosis and underdiagnosis, and identify challenges in the diagnostic process along with factors influencing current diagnostic trends. Material and methods. A literature review was conducted using PubMed, Frontiers, and Google Scholar. The analysis was grounded in DSM-5 criteria, Conners 3, and DIVA-5 questionnaires. NICE guidelines were incorporated to evaluate methodological rigor and temporal demands required for valid clinical assessments. Results. Data indicate an increase in ADHD diagnoses from 6.1% in 1997 to 10.2% in 2016. Longitudinal analysis reveals an escalation linked to the COVID-19 pandemic. Pre-pandemic, adult diagnoses averaged 8.8 per 100,000 population monthly. During 2020–2021, this rose to 19.2/100,000 (a 4.9% month-over-month increase). Post-pandemic reached an average of 34.8/100,000. Conclusions. Despite the noticeable increase in diagnostic rates reported in clinical settings, there remains a lack of solid epidemiological evidence demonstrating a rise in the prevalence of ADHD within the general population within the last decade. Currently, the data does not support a rise in ADHD prevalence, rather it reflects shifts in awareness, diagnostic practices, and health-care seeking behaviors.

7 May 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
SPSzymon Paruszewski
Szymon Paruszewski
ADAleksandra Dybcio
Aleksandra Dybcio
MJMikołaj Jońca
Mikołaj Jońca
MKMikhail Kazachok
Mikhail Kazachok
AKAdam Kubisa
Adam Kubisa
DSDorota Szydłowska
Dorota Szydłowska
Introduction: Pelvic floor muscle dysfunction disorders are a widespread and frequently undiagnosed health problem among women across all age groups. They can result in urinary and fecal incontinence, pelvic organ prolapse, and chronic pain, significantly reducing women’s quality of life. Conservative treatment, particularly pelvic floor muscle training (PFMT), is currently recognized as a highly effective first-line therapy. Purpose: This review aims to present the role of pelvic floor muscle training (PFMT) in improving women’s health and quality of life, with a particular focus on the effectiveness of this form of therapy in the prevention and treatment of pelvic floor muscle dysfunction disorders. A brief description of the state of knowledge: The pelvic floor muscles are crucial for holding urine and stool, keeping the pelvic organs in place, and supporting sexual function. Their dysfunction is linked to many risk factors, such as age, vaginal delivery, obesity, and lifestyle. Pelvic floor muscle training (PFMT) improves muscle tone and strength, leading to reduced symptoms, most commonly urinary incontinence. Pelvic floor muscle training (PFMT) also contributes to improving quality of life in physical, mental, and social dimensions. Biofeedback or electrostimulation are supportive methods, which can further enhance the effectiveness of therapy. Conclusions: Pelvic floor muscle training (PFMT) is an effective and safe method for the prevention and treatment of pelvic floor dysfunction disorders in women. It contributes to a significant improvement in symptoms and quality of life. An individualized and holistic approach to the patient is recommended, incorporating education and a supervised exercise program to ensure the effectiveness of therapy.

10 April 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
KKKatarzyna Kupczyk
Katarzyna Kupczyk
MKMikhail Kazachok
Mikhail Kazachok
SPSzymon Paruszewski
Szymon Paruszewski
ADAleksandra Dybcio
Aleksandra Dybcio
MJMikołaj Jońca
Mikołaj Jońca
JKJulia Kupczak
Julia Kupczak
Introduction: Klinefelter syndrome is the most common chromosomal abnormality in males, characterized by the presence of an extra X chromosome, resulting in 47, XXY karyotype. Its prevalence is approximately 1 in 500 to 1 in 1,000 live-born males. The phenotypic expression is highly variable and includes hypogonadism, infertility, and an increased risk of metabolic complications and neurocognitive disorders. Purpose: The aim of this review is to provide a comprehensive synthesis of the current state of knowledge on Klinefelter syndrome, with particular emphasis on modern diagnostic and therapeutic approaches. Material and methods: This article is a narrative literature review and was conducted using international databases. Publications were selected based on their scientific value, relevance, and relation to the topic. Results: Current evidence indicates that patients benefit from an interdisciplinary approach, involving coordinated care among multiple specialists, including andrologists, endocrinologists, geneticists, psychologists, and experts in infertility treatment. Despite its relatively high prevalence, a significant proportion of affected individuals remain undiagnosed until adulthood, resulting in delayed initiation of therapeutic interventions. Conclusions: Klinefelter syndrome is a genetic condition with numerous somatic, reproductive, and psychosocial consequences. Early diagnosis, individualized therapeutic strategies, and multidisciplinary care significantly improve long-term prognosis and quality of life in patients. Future research should prioritize the refinement of diagnostic approaches, elucidation of the long-term effects of hormone therapy, and investigation of the molecular mechanisms underlying phenotypic variability.

25 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MJMikołaj Jońca
Mikołaj Jońca
NKNatasza Kurys
Natasza Kurys
MKMikhail Kazachok
Mikhail Kazachok
SPSzymon Paruszewski
Szymon Paruszewski
JKJulia Kupczak
Julia Kupczak
MMMateusz Miluski
Mateusz Miluski
Background: Migraine is a common, debilitating and one of the most disabling of the neurovascular disorders. The common treatment has been based on non-specific medications derived from other clinical disciplines such as beta-blockers, antiepileptics and antidepressants, which have variable efficacy and many unwanted side effects and are therefore frequently discontinued. The recent knowledge about the involvement of CGRP and its receptors in migraine pathophysiology has opened new avenues for anti-migraine treatment. Objectives: The aim of this paper is to comprehensively review the mechanism of action, clinical efficacy, safety profile, and comparative effectiveness of erenumab - the first fully human monoclonal antibody designed specifically for migraine prevention. Methods: A narrative review of the current medical literature was conducted using the PubMed database. The analysis included data from phase 2, 3 and 4 randomized controlled trials, long-term open-label extensions, and current international neurological guidelines. Results: Erenumab is a monoclonal antibody that selectively targets the canonical CGRP receptor and functions as a competitive receptor antagonist. Binding of erenumab to the CGRP receptor does not result in vasoconstriction and does not interact with the CYP450 enzyme system. Studies including STRIVE, ARISE and LIBERTY trials have demonstrated the high efficacy of erenumab in the reduction of MMD in both EM and CM patients, including those who have failed multiple prior prophylactic treatments. The HER-MES trial has further confirmed the high tolerability of erenumab and a higher retention rate compared to topiramate. The safety profile is highly favorable, with injection site reactions and constipation being the most frequently reported adverse events. Furthermore, erenumab can safely be given alongside with novel acute treatments, such as gepants and ditans. Conclusions: Erenumab holds great promise in migraine prophylaxis as it’s offering a targeted, highly effective, and well-tolerated therapeutic option. Future research should focus on its long-term efficacy in a real-world setting. One important aspect will be to explore its safety during pregnancy and in children. An interesting and potentially clinically useful aspect for non-responders will be exploring the possibility of combining it with antibodies against other neuropeptide pathways, such as those involving PACAP.

18 October 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
NKNatasza Kurys
Natasza Kurys
MJMikołaj Jońca
Mikołaj Jońca
MKMikhail Kazachok
Mikhail Kazachok
SPSzymon Paruszewski
Szymon Paruszewski
JKJulia Kupczak
Julia Kupczak
MMMateusz Miluski
Mateusz Miluski
Geographic atrophy (GA) is still an important global health concern, especially for patients over 50 years, as it represents a late stage of dry age-related macular degeneration (AMD) and accounts for a large portion of permanent central vision loss. The pathogenesis of GA is complex and multifactorial, including oxidative stress, chronic inflammation, abnormalities in the vitamin A visual cycle and progressive disfunction of the retinal pigment epithelium (RPE). The chronic activation of the complement system, particularly the alternative pathway, is fundamental in the degeneration of RPE cells and photoreceptors. In addition, genetic factors, in particular genetic variants of complement regulatory genes, further increase the risk of disease and can accelerate its progression. Until recently, treatment options were limited to antioxidant supplements based on Age-Related Eye Disease Study (AREDS and AREDS2) recommendations, which demonstrated average effectiveness in slowing disease progression. However, the emergence of medications targeting the complement system marked a turning point. Pegcetacoplan, the C3 inhibitor, and avacincaptad pegol, the C5 inhibitor, have been shown to slow down GA the progression. Although these drugs do not improve visual acuity, they change the natural course of the disease. The difference in the target of the complement cascade may influence the safety of treatment. However, there is still a need for further research to optimize treatment and individualize therapy for patients with GA.